Navigation Links
Biodel Inc. to Announce First Quarter Fiscal Year 2008 Financial Results on February 14, 2008
Date:2/8/2008

DANBURY, Conn., Feb. 8 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that its first quarter fiscal year 2008 financial results will be released on Thursday, February 14, 2008. Following the issuance of its financial results, Biodel's senior management team will host a conference call to discuss first quarter results and provide an update on the Company's developments.

February 14, 2008 Schedule:

8:00 a.m. ET Q1 2008 results will be distributed by PR Newswire

8:20 a.m. ET To participate in the conference call dial:

1-877-545-1407 (United States) or

1-719-325-4920 (International)

8:30 a.m. ET Conference call begins

Interested parties may access a live audio webcast of the conference call in the investor section of Biodel's website at http://www.biodel.com. The audio webcast will be archived and available for replay at the same location.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA- approved peptide drugs. The Company's lead product candidate, VIAject(TM), is a rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company's website at http://www.biodel.com.

Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward- looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, our ability to secure FDA approval for our product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our ability to market, commercialize and achieve market acceptance for product candidates developed using our VIAdel(TM) technology; the progress or success of our research, development and clinical programs, the initiation and completion of our clinical trials, the timing of the interim analyses and the timing or success of our product candidates, particularly VIAject(TM) and VIAtab(TM); our ability to secure additional patents for VIAject(TM) and our other product candidates; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; our estimates of future performance; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of those collaborations after consummation, if consummated; the rate and degree of market acceptance and clinical utility of our products; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our Quarterly Report on Form 10-Q for the quarter ended December 31, 2007. The Company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.
BIOD-G


'/>"/>
SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biodel Inc. Announces Pricing of Public Offering
2. Biodel to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on December 11, 2007
3. Brian J.G. Pereira, M.D. Joins Biodels Board of Directors
4. Biodel Inc. to Present at Natixis Bleichroeder Hidden Gems Conference on October 8, 2007
5. Biodel Inc. to Present at BIO InvestorForum 2007 Conference on October 11, 2007
6. Biodel to Amend June 30, 2007 10-Q to Correct Non-Cash Share-Based Compensation Expense
7. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
8. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
9. Kosan Announces February 28, 2008 Conference Call and Webcast
10. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
11. Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 15, 2017 After spending the past two years building ... data collection, GeneFo now offers this platform to healthcare stakeholders (hospitals, ... support, adherence, and data collection vis a vis their members, under ... successful launch of this offer. ... GeneFo ...
(Date:8/15/2017)... , ... August 15, 2017 , ... ... family of 6” modular downlights designed to stay tightly sealed and perform efficiently ... where damp and wet location listings just aren't enough, such as: hospitals; behavioral ...
(Date:8/14/2017)... ... 2017 , ... Opal Kelly, a leading producer of powerful ... the release of SYZYGY™, a new open standard for connecting high-performance peripherals to ... low cost, low pin-count, high-performance connectivity solution between FPGAs and single-purpose hardware peripherals. ...
(Date:8/11/2017)... ... August 11, 2017 , ... “There ... particular, more natural alternatives to synthetic ingredients,” said Matt Hundt, President of Third ... the established manufacturing presence and know-how of Biorigin will allow us to bring ...
Breaking Biology Technology:
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/24/2017)... 2017 The Controller General of Immigration from Maldives ... Algeen have received the prestigious international IAIR Award for the most ... Reading ... Maldives ... Abdulla Algeen (small picture on the right) have received the IAIR award ...
Breaking Biology News(10 mins):